{"id":20264,"date":"2022-12-19T21:23:41","date_gmt":"2022-12-19T15:53:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20264"},"modified":"2023-04-17T15:21:15","modified_gmt":"2023-04-17T09:51:15","slug":"ash-abstracts-in-the-follicular-lymphoma-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market","title":{"rendered":"ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market"},"content":{"rendered":"\n<p>American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their results for follicular lymphoma (FL).<\/p>\n\n\n\n<p><strong>The key abstracts have been summarized in the table below:<\/strong><\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"590\">\n\t<colgroup>\n\t\t<col width=\"102\">\n\t\t<col width=\"113\">\n\t\t<col width=\"83\">\n\t\t<col width=\"94\">\n\t\t<col width=\"88\">\n\t\t<col width=\"68\">\n\t\t<col width=\"42\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug regimen<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Abstract Title<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Trial ID<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Class<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ORR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ce223d; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:10pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Odronextamab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Odronextamab in Patients with Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) Grade 1\u00e23a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03888105<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(ELM-2)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Regeneron Pharmaceuticals<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">81%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">75%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Zandelisib<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"><sup style=\"font-size:0.6em\">1<\/sup><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(ME-401)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R\/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT03768505<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(TIDAL)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">MEI Pharma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">phosphatidylinositol 3-kinase (PI3K) delta inhibitor<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">85%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">42%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Polatuzumab vedotin + Lenalidomide + Obinutuzumab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">A Phase Ib\/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed\/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT02600897<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Hoffmann-La Roche<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Antibody Drug Conjugate<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">91%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">72%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mosunetuzumab<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"><sup style=\"font-size:0.6em\">2<\/sup><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I\/II Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT02500407<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(GO29781)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Roche<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Bispecific antibody<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">77.8%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">60%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:102px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Iberdomide + Obinutuzumab<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:12pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"><sup style=\"font-size:0.6em\">3<\/sup><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:113px\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed\/Refractory Lymphoma: Early Results from a Phase 1\/2 Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:83px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">NCT04464798<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:94px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">BMS<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:88px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Immunomodulatory imide drug (IMiDs)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:68px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">69%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #bfbfbf; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #bfbfbf; border-right:1px solid #bfbfbf; border-left:1px solid #bfbfbf; width:42px\">\n\t\t\t<p style=\"line-height:1.2; margin-top:16px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:9pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Cambria,serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">39%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<p><strong>Notes:<\/strong><\/p>\n\n\n\n<p>1. MEI Pharma and Kyowa Kirin announced discontinuing Zandelisib development outside of Japan for B-cell malignancies. Moreover, Kyowa Kirin is continuing the ongoing clinical trials, including the Phase II MIRAGE study evaluating Japanese patients with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-non-hodgkin-lymphoma-market\">relapsed or refractory indolent B-cell non-Hodgkin lymphomas<\/a><\/strong> and will explore the potential for submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.<\/p>\n\n\n\n<p>2. Lunsumio (mosunetuzumab) is already approved by European Commission in June 2022 for the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-pipeline-insight\">treatment of people with R\/R Follicular Lymphoma<\/a><\/strong> who have received at least two prior systemic therapies. Additionally, it was the first and only fixed-duration bi-specific antibody to be approved in Europe for lymphoma. Moreover, Lunsumio is under Priority Review with the FDA, with a decision expected by 29 December 2022.<\/p>\n\n\n\n<p>3. Novel CELMoD (Cereblon E3 ligase modulators) is being evaluated for the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights\">treatment of R\/R Follicular Lymphoma<\/a><\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-pipeline-insight\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-1024x256.png\" alt=\"\" class=\"wp-image-22265\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/17152021\/Follicular-lymphoma-pipeline-insight-and-analysis.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their results for follicular lymphoma (FL). The key abstracts have been [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":20287,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18917,20012,20014,20013,18834,20047,18833,18835,20048,18919,20008,20046],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-20264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ash","tag-ash-2022","tag-ash-2022-abstracts","tag-ash-annual-meeting","tag-follicular-lymphoma","tag-follicular-lymphoma-clinical-trials","tag-follicular-lymphoma-market","tag-follicular-lymphoma-pipeline","tag-follicular-lymphoma-treatment","tag-healthcare-conference","tag-healthcare-conferences-2022","tag-healthcare-events","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ASH 2022 | Top Abstracts In the Follicular Lymphoma (FL) Market<\/title>\n<meta name=\"description\" content=\"Major pharma companies to present key abstracts in the Follicular Lymphoma Therapeutics Market at American Society of Hematology (ASH) 2022\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASH 2022 | Top Abstracts In the Follicular Lymphoma (FL) Market\" \/>\n<meta property=\"og:description\" content=\"Major pharma companies to present key abstracts in the Follicular Lymphoma Therapeutics Market at American Society of Hematology (ASH) 2022\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-19T15:53:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-17T09:51:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ASH 2022 | Top Abstracts In the Follicular Lymphoma (FL) Market","description":"Major pharma companies to present key abstracts in the Follicular Lymphoma Therapeutics Market at American Society of Hematology (ASH) 2022","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market","og_locale":"en_US","og_type":"article","og_title":"ASH 2022 | Top Abstracts In the Follicular Lymphoma (FL) Market","og_description":"Major pharma companies to present key abstracts in the Follicular Lymphoma Therapeutics Market at American Society of Hematology (ASH) 2022","og_url":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-19T15:53:41+00:00","article_modified_time":"2023-04-17T09:51:15+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market","url":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market","name":"ASH 2022 | Top Abstracts In the Follicular Lymphoma (FL) Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1.png","datePublished":"2022-12-19T15:53:41+00:00","dateModified":"2023-04-17T09:51:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Major pharma companies to present key abstracts in the Follicular Lymphoma Therapeutics Market at American Society of Hematology (ASH) 2022","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ash-abstracts-in-the-follicular-lymphoma-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1.png","width":772,"height":482,"caption":"Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market at the ASH 2022"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/19212114\/Top-Abstracts-In-the-Follicular-Lymphoma-FL-Therapeutics-Market-at-the-ASH-2022-1-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASH 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASH 2022 Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare Conferences 2022<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Healthcare Events<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ASH<\/span>","<span class=\"advgb-post-tax-term\">ASH 2022<\/span>","<span class=\"advgb-post-tax-term\">ASH 2022 Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conferences 2022<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Events<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Dec 19, 2022","modified":"Updated on Apr 17, 2023"},"absolute_dates_time":{"created":"Posted on Dec 19, 2022 9:23 pm","modified":"Updated on Apr 17, 2023 3:21 pm"},"featured_img_caption":"Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market at the ASH 2022","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20264"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20287"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20264"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20264"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}